Detalhe da pesquisa
1.
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Eur J Haematol
; 97(5): 461-470, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993060
2.
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
Cancer Invest
; 33(8): 378-86, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26115098
3.
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Br J Haematol
; 171(3): 432-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25855517
4.
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer.
Immunooncol Technol
; 3: 1-7, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35757302
5.
The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.
J Mol Biol
; 347(5): 1005-14, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15784259
6.
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
J Hematol Oncol
; 9(1): 50, 2016 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27353420
7.
Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry.
Clin Chem
; 54(9): 1584-6, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18755914
8.
Histone methyltransferases in Aspergillus nidulans: evidence for a novel enzyme with a unique substrate specificity.
Biochemistry
; 43(33): 10834-43, 2004 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15311944